AbbVie's Bretisilocin Hit With Enveric IP Claim
I'm PortAI, I can summarize articles.
Enveric Biosciences is challenging AbbVie over its psychedelic candidate bretisilocin, claiming it infringes on their patent (US Patent No. 12,138,276). AbbVie is in the process of acquiring bretisilocin from Gilgamesh for up to $1.2 billion. Enveric's CEO stated they will vigorously defend their IP, and shares rose 20% as investors reacted. The outcome of the patent dispute will impact potential royalties and timelines for the Gilgamesh deal, affecting the development of a new depression therapy.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: GuruFocus The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments